New Study Offers Hope for Breast Cancer Survivors: HRT Risks and Benefits Balanced
A new study offers fresh insights into the use of hormone replacement therapy (HRT) for breast cancer survivors, who often face severe menopausal symptoms. The research, published in the journal The Lancet, suggests a more nuanced approach to HRT, balancing risks and benefits.
The study found that systemic HRT can slightly increase the risk of breast cancer relapse in women with oestrogen receptor-positive breast cancer, particularly within the first 5-10 years after diagnosis. However, this increased risk is mainly due to local relapses or a second breast cancer, which are usually treatable.
Many breast cancer survivors experience severe menopausal symptoms due to treatment or natural menopause, limiting their treatment options. HRT is the most effective treatment for these symptoms, but it has traditionally been discouraged due to potential recurrence risks. The study provides a more patient-centered approach, emphasizing shared decision-making based on individual symptoms, cancer history, and personal preferences.
The panel recommended enrolling patients considering HRT after breast cancer in clinical trials like the proposed MENO-ABC trial. They also highlighted that vaginal oestrogen is unlikely to increase the risk of breast cancer recurrence and can be used to treat genitourinary symptoms in breast cancer survivors.
Breast cancer is the most common cancer among women worldwide, with 2.3 million women diagnosed annually. The new study and expert consensus statement offer a more balanced view of HRT for breast cancer survivors, acknowledging its effectiveness in managing menopausal symptoms while also considering the potential risks. The key lies in shared decision-making between patients and healthcare providers, tailored to individual circumstances.
